Key Highlights

  • Cooper Companies reported record fiscal Q2 2026 Revenue of $1.082 billion, up 8% year-over-year (5% organically), with non-GAAP EPS of $1.21 beating the $1.10 consensus by 10% and non-GAAP Margin/">Operating Margin expanding to 27%.
  • Management reached agreements to resolve over 95% of claims tied to CooperSurgical's December 2023 embryo culture media recall, booking a $271.6 million net pre-tax charge to substantially put the litigation overhang behind it.
  • COO gained 8.58% on Volume more than four times its average, outperforming sharply against a session where the S&P 500 fell 2.6%, with a median analyst price target of approximately $85 implying meaningful upside from current levels.

Earnings Beat and Overhang Resolution Drive the Session

Shares of The Cooper Companies, Inc. (Nasdaq: COO) closed at $67.34 on June 5, 2026, up 8.58% from a previous close of $61.99, on volume of 9.09 million shares at more than four times the daily average. Cooper Companies is a global medical device company operating two primary segments: CooperVision, a leading manufacturer of contact lenses, and CooperSurgical, a provider of fertility, genomics, and women's health products and services. The stock outperformed sharply against a difficult macro backdrop, with the S&P 500 declining 2.6% on the same session amid a strong jobs report and a broad technology selloff, underscoring the strength of the healthcare-specific catalysts driving the move.

Record Revenue and Margin Expansion

Fiscal Q2 2026 revenue reached a record $1.082 billion, an 8% year-over-year increase and 5% on an organic basis, coming in ahead of analyst estimates. Non-GAAP EPS of $1.21 topped the $1.10 consensus by approximately 10%, and non-GAAP operating margin expanded to 27%, signalling improving operational Leverage across the Business. The combination of a revenue record and margin expansion in the same quarter provided a more constructive picture of the underlying business trajectory for investors monitoring the litigation situation.

Recall Settlement Removes a Structural Overhang

The CooperSurgical embryo culture media recall, disclosed in December 2023, had created a persistent litigation overhang on the stock. Management announced it has reached agreements to resolve over 95% of the related claims, booking a $271.6 million net pre-tax charge to substantially put the matter behind the company. Absorbing a defined charge removes the open-ended uncertainty that had weighed on the valuation, restoring the ability to assess the business on its operating merits.

CooperSurgical Strategic Review Adds Optionality

The reported CooperSurgical strategic review, with interest from potential buyers, introduces M&A optionality beyond the organic operating case. Multiple analysts maintained Buy or Outperform ratings, with a median price target of approximately $85 implying substantial upside from current levels.

Valuation and Risk Considerations

COO trades at a P/E of 33.50 on EPS of $2.01, with a Market Capitalisation of $13.14 billion. The 52-week range of $58.89 to $89.83 contextualises the significant distance between current levels and prior highs, suggesting the stock has room to recover if operational execution and litigation clarity are sustained. Key risks include the remaining 5% of unresolved recall claims, integration and execution demands across both business segments, and broader macroeconomic sensitivity affecting elective medical procedures.

Conclusion

Cooper Companies' 8.58% session advance reflects a convergence of fundamental catalysts: a record revenue quarter, a meaningful earnings beat, margin expansion, and near-complete resolution of the litigation overhang that had suppressed the valuation. Sustaining the momentum will require continued execution in both CooperVision and CooperSurgical, with the strategic review outcome representing the most significant near-term value catalyst.